MA-PRESS-GANEY/FORSTA
27.4.2022 15:02:07 CEST | Business Wire | Press release
Press Ganey , renowned leader in patient, member, employee and consumer experience across the healthcare ecosystem, announced it has completed its acquisition of Forsta , a leading global provider of market research, customer experience (CX) and employee experience (EX) technology. The closing is effective as of April 26, 2022.
As industry-recognized leaders, with Press Ganey recently selected Best in KLAS for Patient Experience Improvement and Forsta named a Leader in the 2021 Gartner® Magic Quadrant™ for Voice of the Customer , the combined companies will power the future of research and experience technology.
“Together, Press Ganey and Forsta offer our clients the data connectivity, accelerated analytics, DEI expertise and deeply segmented insights that companies need to deliver frictionless experiences and truly drive transformation,” said Patrick T. Ryan, chairman and chief executive officer, Press Ganey. “With Forsta, we expand into new geographies and industries, with highly complementary market research, CX and EX technology that will coordinate seamlessly with our existing healthcare solutions.”
“Press Ganey is expediting Forsta’s mission to reinvent the global insights industry. With this investment, we will be able to greatly accelerate innovation so our customers can deliver better insights, faster and at scale,” said Kyle Ferguson, chief executive officer, Forsta. “There is tremendous opportunity from the convergence of our resources, and we have no plans to slow down.”
Acquisition Highlights
Fast-tracked Product Innovation. Press Ganey’s investment will advance Forsta’s product innovation at an accelerated pace, especially in the high-demand areas of artificial intelligence (AI), data visualization and qualitative research.
Marketplace Expansion. Forsta’s global presence and extensive network will propel Press Ganey’s international healthcare growth ambitions while also expanding the company into new verticals, such as retail, financial services and consumer goods.
Unparalleled Insights. Both companies are proven changemakers and bring proprietary research and thought leadership to deliver key insights that tackle essential issues, like barriers to human-centered data , employee burnout and advancing health equity .
Healthcare Sector Disruption. Backed by blue-chip consulting, unparalleled experience measurement expertise and proprietary analytics to help drive improvement, Press Ganey will offer breakthrough advancements to the evolving healthcare marketplace. A new suite of purpose-built for healthcare, self-service solutions are immediately available, like digital communities, virtual focus groups, crowdsourcing and more.
Exceptional Human Capital. Two empowered, elite workforces will come together around aligned missions and pursuits to seamlessly turn data into meaningful insights that drive impact.
The joint company will continue to be led by Ryan as chairman and CEO, and Ferguson will remain at the helm of Forsta as CEO. Combined, the organization’s 3,000+ employees now serve thousands of customers, including Fortune 500 companies and top healthcare systems, throughout the North America, EMEA (Europe-Middle East-Africa) and APAC (Asia-Pacific) regions.
About Press Ganey
Press Ganey invented the healthcare performance improvement movement over 35 years ago. Today it offers an integrated suite of solutions that address safety, clinical excellence, patient experience and workforce engagement. The company works with more than 41,000 healthcare facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality and experience of care.
About Forsta
Forsta powers an Experience and Research Technology Platform that gathers and analyzes data, and translates the findings into shareable actions to inform decision-making and drive growth. Forsta’s technology, combined with its team of expert consultants, help organizations better understand the full Human Experiences (HX) of their audiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005008/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom